1259279-57-6

Basic information

• Product Name: 5-Fluoro-1-tosyl-7-azaindole-3-boronic acid pinacol ester
• Synonyms: 5-Fluoro-1-tosyl-7-azaindole-3-boronic acid pinacol ester;5-fluoro-1-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine;1H-Pyrrolo[2,3-b]pyridine, 5-fluoro-1-[(4-methylphenyl)sulfonyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-;5-Fluoro-1-[(4-methylphenyl)sulfonyl]-7-azaindole-3-boronic acid pinacol ester;5-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine;EOS-60353
• CAS NO: 1259279-57-6
• Molecular Formula: C₂₀H₂₂BFN₂O₄S
• Molecular Weight: 434.2893632
• Mol File: 1259279-57-6.mol

Chemical Properties

• Boiling Point: 574.5±60.0 °C(Predicted)
• Appearance: /
• Density: 1.28±0.1 g/cm3(Predicted)
• Vapor Pressure: 0-0Pa at 20-25℃
• PKA: -1.05±0.30(Predicted)
• CAS DataBase Reference: 5-Fluoro-1-tosyl-7-azaindole-3-boronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Fluoro-1-tosyl-7-azaindole-3-boronic acid pinacol ester(1259279-57-6)
• EPA Substance Registry System: 5-Fluoro-1-tosyl-7-azaindole-3-boronic acid pinacol ester(1259279-57-6)

Safety Data

• Hazardous Substances Data: 1259279-57-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Fluoro-1-tosyl-7-azaindole-3-boronic acid pinacol ester is used as a building block for the synthesis of complex organic molecules. Its unique properties, including strong bonding ability with carbon and oxygen atoms, make it suitable for various organic transformations.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 5-Fluoro-1-tosyl-7-azaindole-3-boronic acid pinacol ester is used as a key intermediate in the development of drug candidates. Its unique structural features and reactivity contribute to the design and synthesis of novel therapeutic agents.
Used in Suzuki-Miyaura Coupling Reactions:
5-Fluoro-1-tosyl-7-azaindole-3-boronic acid pinacol ester is employed as a coupling partner in Suzuki-Miyaura coupling reactions, a widely used method for forming carbon-carbon bonds. Its boronic acid functionality allows for the formation of strong bonds with carbon atoms, facilitating the synthesis of biaryl compounds and other complex molecular structures.
Used in the Synthesis of Bioactive Compounds:
Due to its unique structural features and reactivity, 5-Fluoro-1-tosyl-7-azaindole-3-boronic acid pinacol ester is utilized in the synthesis of bioactive compounds with potential applications in various therapeutic areas. Its incorporation into molecular frameworks can lead to the discovery of new drugs with improved pharmacological properties.
Overall, 5-Fluoro-1-tosyl-7-azaindole-3-boronic acid pinacol ester is a versatile and valuable compound in the fields of organic synthesis and medicinal chemistry, with applications spanning from the development of complex organic molecules to the creation of innovative drug candidates.

Upstream product

• 1190309-71-7 3-bromo-5-fluoro-1H-pyrrolo-[2,3-b]pyridine 
• 866318-99-2 5-fluoro-1-tosyl-1H-pyrrolo [2,3-b]pyridine 
• 73183-34-3 bis(pinacol)diborane 
• 869557-43-7 3-bromo-5-fluoropyridin-2-amine 
• 936344-74-0 3-ethynyl-5-fluoro-pyridin-2-ylamine 
• 866319-00-8 5-fluoro-1H-pyrrolo[2,3‐b]pyridine 
• 21717-96-4 2-amino-5-fluoropyridine 
• 823218-51-5 5-fluoro-3-iodo-pyridin-2-amine 
• 866319-01-9 5-fluoro-3-(2-trimethylsilylethynyl)pyridine-2-amine 
• 98-59-9 p-toluenesulfonyl chloride 
• 1417421-99-8 3-bromo-5-fluoro-1-(p-toluenesulfonyl)-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 1259367-12-8 2-((1S,3S)-3-(5-fluoro-2-(5-fluoro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-ylamino)-1-hydroxycyclohexyl)ethanenitrile 

Relevant articles and documents

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies. We screened our compound library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase. A particular scaffold of interest, the 1H-pyrrolo[2,3-b]pyridine series (7-azaindoles), was selected for further optimization in part on the basis of binding affinity (Ki) as well as on the basis of cellular potency. Optimization of this chemical series led to the identification of VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). On the basis of these findings, it appears that VX-509 offers potential for the treatment of a variety of autoimmune diseases.

ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE

The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

FORMULATIONS OF AZAINDOLE COMPOUNDS

The present invention relates to pharmaceutical compositions, each comprising a multitude of granules that make up an intragranular phase of the composition, wherein the granules are produced by fluid bed granulation and comprise a HCI salt of Compound (1

PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION

Provided herein are compounds of Formula A, B or C that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

Novel heterocyclic compounds and medicinal application of same as anti-influenza virus inhibitors

The invention provides heterocyclic compounds represented by a formula (I) as described in the specification or a pharmaceutically acceptable salt thereof, a preparation method thereof, and application of the heterocyclic compounds to the preparation of m

Heterocyclic compounds and, their compositions and their use as anti-influenza virus drugs (by machine translation)

The invention provides a class of heterocyclic (I) compounds or pharmaceutically acceptable salts thereof as shown in formula (I) or a preparation method thereof as well A as a preparation method and application of the compounds in. preparation of drugs for treating or, preventing influenza viruses RNA. (by machine translation)

Influenza virus replication inhibitors and uses thereof (by machine translation)

The invention provides a compound as an influenza virus replication inhibitor, a method for preparing the same, a pharmaceutical composition containing the compound and application. (by machine translation)

INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF

The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the manufacture of medicaments for treating of influenza.

Influenza virus replication inhibitor and application thereof

The invention provides a type of compounds serving as an influenza virus replication inhibitor, a preparation method of the compounds, a pharmaceutical composition comprising the compounds, and application of the compounds and the pharmaceutical composition thereof in treatment of influenza.

PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas l-lll, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.